Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595123 | 1.00 | KIF11 (0.38) | KIF11BRD4P2RY14SLC6A2DHODH | |
| SCHEMBL4803591 | 0.80 | PARP1 (0.43) | BRD4 | |
| SCHEMBL4890671 | 0.77 | KIF11 (0.38) | KIF11P2RY14SLC6A2DHODHTDP2 | |
| SCHEMBL4899632 | 0.77 | KIF11 (0.38) | KIF11P2RY14SLC6A2DHODHTDP2 | |
| Trifluoroacetic Acid SCHEMBL4596431 | 0.72 | KIF11 (0.42) | KIF11BRD4P2RY14DHODHTDP2 | |
| Trifluoroacetic Acid SCHEMBL4595122 | 0.72 | KIF11 (0.42) | KIF11BRD4P2RY14DHODHTDP2 | |
| SCHEMBL4596423 | 0.71 | KIF11 (0.47) | KIF11BRD4TDP2 | |
| SCHEMBL14154359 | 0.71 | KIF11 (0.47) | KIF11BRD4TDP2 | |
| SCHEMBL1562063 | 0.69 | BRD4 (0.43) | KIF11BRD4 | |
| SCHEMBL4888914 | 0.65 | KIF11 (0.41) | KIF11BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885BRD4 1727/4885P2RY14 4762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.